Identification

Name
Betamethasone
Accession Number
DB00443  (APRD00513)
Type
Small Molecule
Groups
Approved, Vet approved
Description

A glucocorticoid given orally, parenterally, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. Its lack of mineralocorticoid properties makes betamethasone particularly suitable for treating cerebral edema and congenital adrenal hyperplasia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p724)

Structure
Thumb
Synonyms
  • 16beta-Methyl-1,4-pregnadiene-9alpha-fluoro-11beta,17alpha,21-triol-3,20-dione
  • 16β-Methyl-1,4-pregnadiene-9α-fluoro-11β,17α,21-triol-3,20-dione
  • 9-Fluoro-16beta-methylprednisolone
  • 9-Fluoro-16β-methylprednisolone
  • 9alpha-Fluoro-16beta-methylprednisolone
  • 9α-Fluoro-16β-methylprednisolone
  • beta-Methasone alcohol
  • Betadexamethasone
  • Betametasona
  • Betamethasone
  • Betamethasonum
  • Betamethasonvalerat Mikron
  • Rinderon
External IDs
NSC-39470 / SCH 4831 / SCH-4831
Product Ingredients
IngredientUNIICASInChI Key
Betamethasone acetateTI05AO53L7987-24-6AKUJBENLRBOFTD-QZIXMDIESA-N
Betamethasone benzoate877K0XW47A22298-29-9SOQJPQZCPBDOMF-YCUXZELOSA-N
Betamethasone dipropionate826Y60901U5593-20-4CIWBQSYVNNPZIQ-XYWKZLDCSA-N
Betamethasone sodium phosphate7BK02SCL3W151-73-5PLCQGRYPOISRTQ-LWCNAHDDSA-L
Betamethasone valerate9IFA5XM7R22152-44-5SNHRLVCMMWUAJD-SUYDQAKGSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Beben Gel 0.025%Gel0.025 %TopicalParke Davis Division, Warner Lambert Canada Inc.1973-12-311999-04-08Canada
Betacort Scalp Lotion 0.1%Liquid.1 %TopicalIcn Pharmaceuticals1981-12-312005-04-26Canada
Betaderm Crm 0.05%Cream0.05 %TopicalTaro Pharmaceuticals, Inc.1979-12-31Not applicableCanada
Betaderm Crm 0.1%Cream0.1 %TopicalTaro Pharmaceuticals, Inc.1979-12-31Not applicableCanada
Betaderm Lotion 0.1%Lotion0.1 %TopicalTaro Pharmaceuticals, Inc.1979-12-31Not applicableCanada
Betaderm Ont 0.05%Ointment0.05 %TopicalTaro Pharmaceuticals, Inc.1979-12-31Not applicableCanada
Betaderm Ont 0.1%Ointment0.1 %TopicalTaro Pharmaceuticals, Inc.1988-12-31Not applicableCanada
Betagel - 0.1%Gel.1 %TopicalUcb Inc1996-12-061998-04-21Canada
Betamethasone DipropionateCream0.5 mg/1gTopicalA-S Medication Solutions1984-06-26Not applicableUs
Betamethasone DipropionateCream0.5 mg/1gTopicalA S Medication Solutions1984-06-26Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BetamethasoneCream0.5 mg/1gTopicalImpax Generics2004-01-232017-06-30Us
Betamethasone DipropionateCream0.64 mg/1gTopicalTaro Pharmaceuticals U.S.A., Inc.1992-04-30Not applicableUs
Betamethasone DipropionateCream0.5 mg/1gTopicalGlenmark Pharmaceuticals Inc.,Usa2008-09-23Not applicableUs
Betamethasone DipropionateLotion0.5 mg/1mLTopicalAlmus1987-08-10Not applicableUs
Betamethasone DipropionateCream0.5 mg/1gTopicalPreferreed Pharmaceuticals Inc.1987-02-032011-02-15Us
Betamethasone DipropionateCream0.5 mg/1gTopicalH.J. Harkins Company1984-02-26Not applicableUs
Betamethasone DipropionateCream0.5 mg/1gTopicalActavis Pharma Company2002-09-03Not applicableUs
Betamethasone DipropionateCream0.5 mg/1gTopicalA-S Medication Solutions2002-09-03Not applicableUs
Betamethasone DipropionateOintment0.5 mg/1gTopicalTeligent Pharma, Inc.2017-10-30Not applicableUs
Betamethasone DipropionateCream, augmented0.5 mg/1gTopicalTaro Pharmaceuticals U.S.A., Inc.2003-12-09Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Beta 1 KitBetamethasone acetate (3 mg/1mL) + Betamethasone sodium phosphate (3 mg/1mL)KitIntra-articular; Intralesional; IntramuscularOaklock, Llc2015-08-25Not applicableUs
Beta 1 KitBetamethasone acetate (3 mg/1mL) + Betamethasone sodium phosphate (3 mg/1mL)KitIntra-articular; Intralesional; IntramuscularOaklock, Llc2015-08-25Not applicableUs
Beta Inject KitBetamethasone acetate (3 mg/1mL) + Betamethasone sodium phosphate (3 mg/1mL) + Lidocaine hydrochloride (10 mg/1mL)KitInfiltration; Intra-articular; Intralesional; Intramuscular; PerineuralOaklock, Llc2014-06-132015-09-09Us
Beta Inject KitBetamethasone acetate (3 mg/1mL) + Betamethasone sodium phosphate (3 mg/1mL) + Lidocaine hydrochloride (10 mg/1mL)KitInfiltration; Intra-articular; Intralesional; Intramuscular; PerineuralOaklock, Llc2014-06-132015-09-09Us
BetajectBetamethasone (3 mg) + Betamethasone acetate (3 mg)SuspensionIntra-articular; Intralesional; IntramuscularSandoz Canada Incorporated1998-07-02Not applicableCanada
BetajectBetamethasone (3 mg) + Betamethasone acetate (3 mg)SuspensionIntra-articular; Intralesional; IntramuscularSandoz Canada Incorporated1998-07-02Not applicableCanada
Betamethasone ClotrimazoleBetamethasone dipropionate (0.64 mg/1) + Clotrimazole (10 mg/1)CreamTopicalStat Rx USA2002-08-02Not applicableUs
Betamethasone Sodium Phosphate and Betamethasone AcetateBetamethasone acetate (3 mg/1mL) + Betamethasone sodium phosphate (3 mg/1mL)Injection, suspensionIntra-articular; Intralesional; IntramuscularRemedy Repack2017-05-09Not applicableUs
Betamethasone Sodium Phosphate and Betamethasone AcetateBetamethasone acetate (3 mg/1mL) + Betamethasone sodium phosphate (3 mg/1mL)Injection, suspensionIntra-articular; Intralesional; IntramuscularAMERICAN REGENT, INC.2010-04-28Not applicableUs
Betamethasone Sodium Phosphate and Betamethasone AcetateBetamethasone acetate (3 mg/1mL) + Betamethasone sodium phosphate (3 mg/1mL)Injection, suspensionIntra-articular; Intralesional; IntramuscularAMERICAN REGENT, INC.2010-04-28Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Betalido KitBetamethasone sodium phosphate (3 mg/1mL) + Betamethasone acetate (3 mg/1mL) + Isopropyl Alcohol (70 mL/100mL) + Lidocaine hydrochloride (10 mg/1mL) + Povidone-iodine (10 mg/1mL)KitInfiltration; Intra-articular; Intralesional; Intramuscular; Perineural; TopicalAsclemed Usa, Inc.2014-06-13Not applicableUs
Betalido KitBetamethasone sodium phosphate (3 mg/1mL) + Betamethasone acetate (3 mg/1mL) + Isopropyl Alcohol (70 mL/100mL) + Lidocaine hydrochloride (10 mg/1mL) + Povidone-iodine (10 mg/1mL)KitInfiltration; Intra-articular; Intralesional; Intramuscular; Perineural; TopicalAsclemed Usa, Inc.2014-06-13Not applicableUs
Betaloan SUIKBetamethasone sodium phosphate (3 mg/1mL) + Betamethasone acetate (3 mg/1mL)Injection, suspensionIntra-articular; Intralesional; IntramuscularAsclemed Usa, Inc.2010-04-28Not applicableUs
Betaloan SUIKBetamethasone sodium phosphate (3 mg/1mL) + Betamethasone acetate (3 mg/1mL)Injection, suspensionIntra-articular; Intralesional; IntramuscularAsclemed Usa, Inc.2010-04-28Not applicableUs
Betamethasone Combo 6mg/mL PFBetamethasone acetate (3 mg/1mL) + Betamethasone sodium phosphate (3 mg/1mL)Injection, suspensionEpidural; Intramuscular; Intraspinal; IntrathecalUs Compounding, Inc2013-12-202015-09-11Us
Betamethasone Combo 6mg/mL PFBetamethasone acetate (3 mg/1mL) + Betamethasone sodium phosphate (3 mg/1mL)Injection, suspensionEpidural; Intramuscular; Intraspinal; IntrathecalUs Compounding, Inc2013-12-202015-09-11Us
Betamethasone Combo 7mg/mLBetamethasone acetate (3 mg/1mL) + Betamethasone sodium phosphate (4 mg/1mL)Injection, suspensionIntramuscularUs Compounding, Inc2013-12-202015-09-11Us
Betamethasone Combo 7mg/mLBetamethasone acetate (3 mg/1mL) + Betamethasone sodium phosphate (4 mg/1mL)Injection, suspensionIntramuscularUs Compounding, Inc2013-12-202015-09-11Us
Betamethasone SP 24mg/2mL PFBetamethasone sodium phosphate (12 mg/1mL)Injection, solutionEpidural; Intramuscular; Intraspinal; IntrathecalUs Compounding, Inc2013-12-202015-09-11Us
Dr. Throwers BetaBetamethasone dipropionate (0.05 g/100g)CreamTopicalDr. Thrower's Skincare, Inc.2015-05-15Not applicableUs
International/Other Brands
Bentelan (Defiante) / Betnovate (GlaxoSmithKline) / Celestamine (Schering-Plough) / Celestone (Schering-Plough) / Diprosone (Schering-Plough) / Fucibet (LEO) / Procort / Rinderon (Shionogi Seiyaku)
Categories
UNII
9842X06Q6M
CAS number
378-44-9
Weight
Average: 392.4611
Monoisotopic: 392.199902243
Chemical Formula
C22H29FO5
InChI Key
UREBDLICKHMUKA-DVTGEIKXSA-N
InChI
InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,17-,19-,20-,21-,22-/m0/s1
IUPAC Name
(1R,2S,10S,11S,13S,14R,15S,17S)-1-fluoro-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,13,15-trimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-5-one
SMILES
[H][C@@]12C[C@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C

Pharmacology

Indication

Topical use (cream, lotion and ointment): for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Topical use (foam): relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp. Systemic use: for the treatment of edocrine disorders, rheumatic disorders, collagen diseases, dermatological diseases, allergic states, ophthalmic diseases, respiratory diseases, hematologic disorders, neoplastic diseases, edematous states, gastrointestinal diseases, tuberculous meningitis and trichinosis.

Associated Conditions
Pharmacodynamics

Betamethasone and its derivatives, betamethasone sodium phosphate and betamethasone acetate, are synthetic glucocorticoids. Used for its antiinflammatory or immunosuppressive properties, betamethasone is combined with a mineralocorticoid to manage adrenal insufficiency and is used in the form of betamethasone benzoate, betamethasone dipropionate, or betamethasone valerate for the treatment of inflammation due to corticosteroid-responsive dermatoses. Betamethasone and clotrimazole are used together to treat cutaneous tinea infections.

Mechanism of action

Betamethasone is a glucocorticoid receptor agonist. This leads to changes in genetic expression once this complex binds to the GRE. The antiinflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. The immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. Betamethasone binds to plasma transcortin, and it becomes active when it is not bound to transcortin.

TargetActionsOrganism
AGlucocorticoid receptor
agonist
Human
Absorption

Minimal if applied topically.

Volume of distribution
Not Available
Protein binding

64%

Metabolism

Hepatic

Route of elimination
Not Available
Half life

5.6 hours

Clearance
Not Available
Toxicity

Symptoms of overdose include burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe metabolism of (R)-warfarin can be increased when combined with Betamethasone.
(S)-WarfarinThe metabolism of (S)-Warfarin can be increased when combined with Betamethasone.
1-TestosteroneThe risk or severity of edema formation can be increased when 1-Testosterone is combined with Betamethasone.
1,10-PhenanthrolineThe therapeutic efficacy of 1,10-Phenanthroline can be decreased when used in combination with Betamethasone.
16-BromoepiandrosteroneThe risk or severity of edema formation can be increased when 16-Bromoepiandrosterone is combined with Betamethasone.
19-norandrostenedioneThe risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Betamethasone.
1alpha-Hydroxyvitamin D5The therapeutic efficacy of 1alpha-Hydroxyvitamin D5 can be decreased when used in combination with Betamethasone.
2-MethoxyethanolThe risk or severity of adverse effects can be increased when Betamethasone is combined with 2-Methoxyethanol.
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Betamethasone.
3,5-diiodothyropropionic acidThe metabolism of 3,5-diiodothyropropionic acid can be increased when combined with Betamethasone.
Food Interactions
  • Take with food to reduce irritation.

References

Synthesis Reference

Fernando AHUMADA AYALA, "SKIN-CARE PREPARATIONS CONTAINING MUPIROCIN AND BETAMETHASONE DIPROPIONATE." U.S. Patent US20100063015, issued March 11, 2010.

US20100063015
General References
Not Available
External Links
Human Metabolome Database
HMDB0014586
KEGG Drug
D00244
PubChem Compound
9782
PubChem Substance
46505155
ChemSpider
9399
BindingDB
73823
ChEBI
3077
ChEMBL
CHEMBL632
Therapeutic Targets Database
DAP001043
PharmGKB
PA164754818
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Betamethasone
ATC Codes
S01CA05 — Betamethasone and antiinfectivesS01BB04 — Betamethasone and mydriaticsH02AB01 — BetamethasoneR03BA04 — BetamethasoneD07BC01 — Betamethasone and antisepticsC05AA05 — BetamethasoneD07CC01 — Betamethasone and antibioticsR01AD06 — BetamethasoneS03BA03 — BetamethasoneA07EA04 — BetamethasoneS02BA07 — BetamethasoneS01CB04 — BetamethasoneD07AC01 — BetamethasoneD07XC01 — BetamethasoneS03CA06 — Betamethasone and antiinfectivesS01BA06 — Betamethasone
AHFS Codes
  • 68:04.00 — Adrenals
  • 84:06.00 — Anti-inflammatory Agents
  • 52:08.00 — Anti-inflammatory Agents
  • 56:36.00 — Anti-inflammatory Agents
  • 52:08.08 — Corticosteroids
FDA label
Download (37.5 KB)
MSDS
Download (71.9 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers1
1CompletedNot AvailablePsoriasis Vulgaris (Plaque Psoriasis)1
1CompletedOtherHealthy Volunteers1
1CompletedOtherPsoriasis1
1CompletedOtherPsoriasis Vulgaris (Plaque Psoriasis)1
1CompletedTreatmentAtopic Dermatitis (AD)1
1CompletedTreatmentPsoriasis3
1CompletedTreatmentPsoriasis Vulgaris (Plaque Psoriasis)2
1CompletedTreatmentPsoriasis / Psoriasis Vulgaris (Plaque Psoriasis)1
1CompletedTreatmentScalp Psoriasis1
1Not Yet RecruitingTreatmentAntenatal Corticosteroids / Premature Births1
1Not Yet RecruitingTreatmentRefractory Neuroblastoma / Relapsed Neuroblastoma1
1RecruitingTreatmentBotulinum Toxins, Type A / Plantar Fascitis1
1RecruitingTreatmentPsoriasis1
1TerminatedTreatmentLeukemias / Myelodysplastic Syndromes1
1, 2CompletedTreatmentArthritis / Psoriasis1
1, 2CompletedTreatmentPsoriasis2
1, 2TerminatedPreventionCongenital Cystic Adenomatoid Malformation (CCAM)1
1, 2Unknown StatusTreatmentCorneal Diseases / Hypermetropia / Myopia / Pterygium1
2Active Not RecruitingTreatmentSickle Cell Disorders1
2CompletedPreventionLung Cancer Non-Small Cell Cancer (NSCLC) / Metastatic Colorectal Cancers1
2CompletedTreatmentHip Pain Etiology Unknown1
2CompletedTreatmentOpen Angle Glaucoma (OAG)1
2CompletedTreatmentOral Lichen Planus / Recurrent Aphthous Stomatitis1
2CompletedTreatmentPruritus in Patients With Atopic Dermatitis1
2CompletedTreatmentPsoriasis Vulgaris (Plaque Psoriasis)2
2Not Yet RecruitingTreatmentAchilles Tendinitis / Lateral Epicondylitis / Rotator Cuff Syndrome1
2Not Yet RecruitingTreatmentLateral Epicondylitis / Rotator Cuff Syndrome1
2RecruitingTreatmentOral Lichen Planus1
2TerminatedTreatmentInjuries, Ankle1
2Unknown StatusPreventionRespiratory Distress Syndrome, Newborn / Transient Tachypnea of the Newborn1
2Unknown StatusTreatmentLate Preterm1
2, 3RecruitingTreatmentPPROM / Respiratory Distress Syndrome In Premature Infants1
2, 3TerminatedPreventionRespiratory Distress Syndrome, Newborn1
2, 3TerminatedTreatmentBronchiolitis / Children1
3Active Not RecruitingPreventionPregnancy / Pregnancy Outcomes / Premature Births / Respiratory Distress / Respiratory Distress Syndrome (RDS)1
3CompletedPreventionPost-Operative Nausea and Vomiting (PONV) / Postoperative Emesis1
3CompletedTreatmentAllergic Rhinitis (AR)1
3CompletedTreatmentAtopic Dermatitis (AD)1
3CompletedTreatmentCarpal Tunnel Syndrome (CTS)1
3CompletedTreatmentCoughing / Throat Pain1
3CompletedTreatmentDermatitis, Eczematous1
3CompletedTreatmentPsoriasis1
3CompletedTreatmentPsoriasis Vulgaris (Plaque Psoriasis)3
3CompletedTreatmentRespiratory Distress Syndrome (RDS)1
3RecruitingTreatmentCommunity Acquired Pneumonia (CAP)1
3RecruitingTreatmentInfected Atopic Dermatitis/Eczema1
3RecruitingTreatmentNeonatal Complications1
3RecruitingTreatmentPsoriasis Vulgaris (Plaque Psoriasis)1
3RecruitingTreatmentScalp Psoriasis1
3TerminatedTreatmentComplications, Pregnancy1
3TerminatedTreatmentCutaneous Hypersensitivity1
3TerminatedTreatmentOral Lichen Planus1
3Unknown StatusTreatmentAllergic Rhinitis (AR)1
3Unknown StatusTreatmentAtopic Dermatitis (AD) / Dermatitis, Contact / Psoriasis / Seborrheic Dermatitis1
3WithdrawnTreatmentPremature Births / Premature Labour1
4CompletedOtherPsoriasis Vulgaris (Plaque Psoriasis)1
4CompletedPreventionHand Eczema1
4CompletedPreventionNeonatal Distress1
4CompletedTreatmentAlopecia Areata (AA)1
4CompletedTreatmentBack Pain / Cervical Pain1
4CompletedTreatmentOsteoarthritis (OA)1
4CompletedTreatmentPsoriasis1
4CompletedTreatmentPsoriasis Vulgaris (Plaque Psoriasis)1
4CompletedTreatmentRhinitis1
4Not Yet RecruitingPreventionChronic Migraine1
4Not Yet RecruitingTreatmentBack Pain Lower Back / Back Pain With Radiation / Radicular; Neuropathic, Lumbar, Lumbosacral1
4Not Yet RecruitingTreatmentTrigger Finger1
4RecruitingPreventionNeonatal Respiratory Distress1
4RecruitingTreatmentDeQuervain Tendinopathy1
4RecruitingTreatmentDeQuervain's Tenosynovitis1
4RecruitingTreatmentKnee Osteoarthritis (Knee OA)1
4RecruitingTreatmentPain, Chronic1
4RecruitingTreatmentPsoriasis Vulgaris (Plaque Psoriasis)2
4RecruitingTreatmentVestibular Diseases / Vestibular Neuronitis1
4TerminatedTreatmentAtopic Dermatitis (AD) / Skin Diseases, Eczematous1
4TerminatedTreatmentPsoriasis Vulgaris (Plaque Psoriasis)1
4WithdrawnTreatmentPhimosis1
Not AvailableCompletedNot AvailablePharmacological Action (PA)1
Not AvailableCompletedNot AvailablePsoriasis Vulgaris (Plaque Psoriasis)1
Not AvailableCompletedPreventionHyaline Membrane Disease / Transient Tachypnea1
Not AvailableCompletedTreatmentBack Pain / Cervical Pain1
Not AvailableCompletedTreatmentDiscoid Lupus Erythematosus (DLE)1
Not AvailableCompletedTreatmentIntraventricular Hemorrhage / Neonatal Mortality / Respiratory Distress Syndrome (RDS)1
Not AvailableCompletedTreatmentPsoriasis1
Not AvailableNot Yet RecruitingNot AvailableHypoglycemia1
Not AvailableRecruitingNot AvailablePsoriasis Vulgaris (Plaque Psoriasis)1
Not AvailableRecruitingPreventionNeonatal Respiratory Distress Syndrome1
Not AvailableTerminatedTreatmentThumb Carpometacarpal Joint Osteoarthritis1
Not AvailableUnknown StatusPreventionEvaluation of pulmonary function / Functional Residual Capacity / Respiratory Compliance1
Not AvailableUnknown StatusTreatmentAutoimmune Diseases / Hepatitis C Viral Infection / Lichen Planus (LP) / Vasculitis1
Not AvailableUnknown StatusTreatmentPlantar Fasciitis, Chronic1
Not AvailableUnknown StatusTreatmentPolymyalgia Rheumatica1
Not AvailableWithdrawnTreatmentBursitis / Tendonitis1

Pharmacoeconomics

Manufacturers
  • Schering corp sub schering plough corp
  • Parke davis div warner lambert co
  • Parke davis pharmaceutical research div warner lambert co
  • Altana inc
  • Glenmark generics inc usa
  • Perrigo new york inc
  • Taro pharmaceuticals usa inc
  • Tolmar inc
  • Schering corp
  • Savage laboratories inc div altana inc
  • Actavis mid atlantic llc
  • E fougera div altana inc
  • Pharmaderm div altana inc
  • Teva pharmaceuticals usa inc
  • Alpharma us pharmaceuticals division
  • Taro pharmaceuticals inc
  • Teva pharmaceuticals usa
  • Watson laboratories inc
  • Connectics corp
  • Tj roaco ltd
  • Pharmafair inc
  • Stat trade inc
Packagers
  • Accra Pac Inc.
  • Actavis Group
  • Advanced Pharmaceutical Services Inc.
  • American Regent
  • A-S Medication Solutions LLC
  • C.O. Truxton Inc.
  • Clint Pharmaceutical Inc.
  • Contract Pharm
  • Crown Laboratories Inc.
  • Darby Dental Supply Co. Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • DPT Laboratories Ltd.
  • E. Fougera and Co.
  • Faithful Friends Homeopathic Inc.
  • Genesis Pharmaceutical Inc.
  • Glenmark Generics Ltd.
  • Hikma Pharmaceuticals
  • Major Pharmaceuticals
  • Martin Surgical Supply
  • Mason Distributors
  • Medisca Inc.
  • Merit Pharmaceuticals
  • Nycomed Inc.
  • Palmetto Pharmaceuticals Inc.
  • Patheon Inc.
  • Perrigo Co.
  • Pharmaforce Inc.
  • Pharmedix
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Qualitest
  • Quality Care
  • Rebel Distributors Corp.
  • SAL Pharma
  • Sandoz
  • Savage Labs
  • Schering Corp.
  • Stat Rx Usa
  • Stiefel Labs
  • Taro Pharmaceuticals USA
  • Teva Pharmaceutical Industries Ltd.
  • Tolmar Inc.
  • Warrick Pharmaceuticals Corp.
Dosage forms
FormRouteStrength
GelTopical0.025 %
KitIntra-articular; Intralesional; Intramuscular
KitInfiltration; Intra-articular; Intralesional; Intramuscular; Perineural
LiquidTopical.1 %
GelTopical.1 %
SuspensionIntra-articular; Intralesional; Intramuscular
KitInfiltration; Intra-articular; Intralesional; Intramuscular; Perineural; Topical
Injection, suspensionEpidural; Intramuscular; Intraspinal; Intrathecal
Injection, suspensionIntramuscular
CreamTopical.64 mg/1g
CreamTopical0.5 mg/1g
CreamTopical0.64 mg/1g
Cream, augmentedTopical0.5 mg/1g
GelTopical.50 mg/1g
GelTopical0.5 mg/1g
GelTopical0.64 mg/1g
LotionTopical0.5 mg/1mL
Lotion, augmentedTopical0.5 mg/1mL
OintmentTopical0.05 mg/1g
OintmentTopical0.5 mg/1g
Ointment, augmentedTopical0.5 mg/1g
LotionTopical0.64 mg/1mL
Injection, suspensionIntra-articular; Intralesional; Intramuscular
Injection, solutionEpidural; Intramuscular; Intraspinal; Intrathecal12 mg/1mL
CreamTopical1 mg/1g
CreamTopical1.2 mg/1g
LotionCutaneous1.0 mg/1mL
LotionTopical1 mg/1mL
OintmentTopical1 mg/1g
OintmentTopical1.2 mg/1g
LotionTopical1.22 mg
CreamTopical.05 %
CreamTopical.64 mg
LotionTopical.64 mg
OintmentTopical.64 mg
PatchTopical0.1 %
Solution / dropsAuricular (otic); Ophthalmic.1 %
LiquidAuricular (otic); Ophthalmic0.1 %
TabletTopical0.1 mg
EnemaRectal5 mg
TabletOral.5 mg
Tablet, effervescentOral0.5 mg
CreamTopical.1 %
LotionTopical.1 %
OintmentTopical.1 %
OintmentTopical0.1 %
OintmentTopical0.05 %
SolutionOral0.6 mg/5mL
Tablet, extended releaseOral1 mg
Injection, suspensionIntra-articular; Intralesional; Intramuscular; Soft tissue
SuspensionIntra-articular; Intrabursal; Intradermal; Intramuscular
TabletOral0.5 mg
Kit
LotionTopical0.5 mg/1g
LotionTopical
OintmentTopical
LiquidAuricular (otic); Ophthalmic
GelTopical
CreamTopical0.05 g/100g
OintmentTopical0.05 g/100g
Aerosol, foamTopical
SolutionAuricular (otic); Ophthalmic
OintmentOphthalmic
CreamTopical
Aerosol, foamTopical0.12 %
Aerosol, foamTopical1.2 mg/1g
KitEpidural; Infiltration; Intra-articular; Intralesional; Intramuscular; Topical
LotionTopical.05 %
CreamTopical0.05 %
LotionTopical0.05 %
CreamTopical0.1 %
KitEpidural; Infiltration; Intra-articular; Intralesional; Intramuscular
CreamTopical0.5 mg
LotionTopical.5 mg
OintmentTopical.5 mg
CreamTopical.5 mg
OintmentTopical.05 %
KitTopical
SprayTopical0.5 mg/1g
Spray, meteredTopical
SuspensionTopical
LotionTopical0.1 %
Prices
Unit descriptionCostUnit
Luxiq 0.12% Foam 100 gm Can325.17USD can
Luxiq 0.12% Foam 50 gm Can174.7USD can
Diprolene 0.05% Lotion 60ml Bottle148.19USD bottle
Diprolene 0.05% Ointment 50 gm Tube147.41USD tube
Diprolene AF 0.05% Cream 50 gm Tube147.02USD tube
Betamethasone Dipropionate Aug 0.05% Ointment 45 gm Tube118.42USD tube
Diprolene 0.05% Gel 50 gm Tube103.99USD tube
Betamethasone Dipropionate Aug 0.05% Lotion 60ml Bottle100.64USD bottle
Betamethasone Dipropionate Aug 0.05% Cream 50 gm Tube88.66USD tube
Betamethasone Dipropionate Aug 0.05% Gel 50 gm Tube88.26USD tube
Diprolene 0.05% Lotion 30ml Bottle78.79USD bottle
Betamethasone acetate powd78.03USD g
Diprolene 0.05% Ointment 15 gm Tube69.38USD tube
Diprolene AF 0.05% Cream 15 gm Tube69.38USD tube
Betamethasone Dipropionate Aug 0.05% Ointment 15 gm Tube58.83USD tube
Betamethasone sod phos powder56.61USD g
Diprolene 0.05% Gel 15 gm Tube49.99USD tube
Betamethasone dp powder48.96USD g
Betamethasone valerate powd47.89USD g
Maxivate 0.05% Cream 45 gm Tube44.99USD tube
Betamethasone Dipropionate 0.05% Lotion 60ml Bottle40.4USD bottle
Betamethasone Dipropionate Aug 0.05% Cream 15 gm Tube39.62USD tube
Betamethasone Dipropionate Aug 0.05% Gel 15 gm Tube39.46USD tube
Betamethasone Dipropionate 0.05% Ointment 45 gm Tube19.67USD tube
Betamethasone Dipropionate 0.05% Cream 45 gm Tube18.9USD tube
Betamethasone Valerate 0.1% Lotion 60ml Bottle16.99USD bottle
Betamethasone Valerate 0.1% Ointment 45 gm Tube15.87USD tube
Beta-Val 0.1% Lotion 60ml Bottle14.99USD bottle
Betamethasone Dipropionate 0.05% Ointment 15 gm Tube13.51USD tube
Betamethasone Dipropionate 0.05% Cream 15 gm Tube12.99USD tube
Betamethasone Valerate 0.1% Cream 45 gm Tube12.99USD tube
Beta-Val 0.1% Cream 45 gm Tube12.99USD tube
Betamethasone Valerate 0.1% Cream 15 gm Tube11.99USD tube
Betamethasone Valerate 0.1% Ointment 15 gm Tube11.99USD tube
Beta-Val 0.1% Cream 15 gm Tube11.99USD tube
Betnesol (5 mg/100Ml) 5 mg/enm Enema9.51USD enema
Celestone soluspan 6 mg/ml8.08USD ml
Betamethasone ac-sp 6 mg/ml vial7.68USD ml
Luxiq 0.12% foam5.01USD g
Diprolene af 0.05% cream4.19USD g
Lotrisone 1-0.05% Lotion2.89USD ml
Lotrisone cream2.71USD g
Betamethasone dp aug 0.05% crm2.17USD g
Diprolene Glycol 0.05 % Glycol Cream0.54USD g
Diprolene Glycol 0.05 % Glycol Ointment0.54USD g
Ratio-Topilene 0.05 % Glycol Cream0.54USD g
Ratio-Topilene 0.05 % Glycol Ointment0.54USD g
Diprolene Glycol 0.05 % Glycol Lotion0.49USD g
Ratio-Topilene 0.05 % Glycol Lotion0.49USD g
Prevex B 0.1 % Occlusive Cream0.4USD g
Beta-val 0.1% cream0.32USD g
Ratio-Ectosone Regular 0.1 % Lotion0.3USD g
Ratio-Ectosone Mild 0.05 % Lotion0.23USD g
Diprosone 0.05 % Ointment0.23USD g
Ratio-Topisone 0.05 % Ointment0.23USD g
Diprosone 0.05 % Cream0.21USD g
Diprosone 0.05 % Lotion0.21USD g
Ratio-Topisone 0.05 % Cream0.21USD g
Ratio-Topisone 0.05 % Lotion0.21USD g
Betamethasone va 0.1% cream0.14USD g
Betaderm Regular 0.1 % Ointment0.1USD g
Ratio-Ectosone Regular 0.1 % Cream0.1USD g
Valisone Scalp 0.1 % Lotion0.1USD g
Betaderm Regular 0.1 % Cream0.09USD g
Ratio-Ectosone Scalp 0.1 % Lotion0.09USD g
Betaderm Mild 0.05 % Ointment0.07USD g
Betaderm Mild 0.05 % Cream0.06USD g
Ratio-Ectosone Mild 0.05 % Cream0.06USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6126920No2000-10-032016-03-01Us
US7078058No2006-07-182017-05-24Us
US6753013No2004-06-222020-01-27Us
US6787529No2004-09-072020-01-27Us
US9119781No2015-09-012031-06-10Us
US9439911No2016-09-132030-08-31Us
US9433630No2016-09-062030-08-31Us
US9655907No2017-05-232030-08-31Us
US9364485No2016-06-142030-08-31Us
US9775851No2017-10-032030-08-31Us
US9877974No2018-01-302030-08-31Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)232 °CU.S. Patent 3,164,618
water solubility66.5 mg/L (at 25 °C)EPA
logP1.94HANSCH,C ET AL. (1995)
logS-3.77ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.0505 mg/mLALOGPS
logP1.93ALOGPS
logP1.68ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)12.42ChemAxon
pKa (Strongest Basic)-3.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area94.83 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity102.49 m3·mol-1ChemAxon
Polarizability40.88 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.992
Blood Brain Barrier+0.9781
Caco-2 permeable+0.8304
P-glycoprotein substrateSubstrate0.7862
P-glycoprotein inhibitor INon-inhibitor0.8112
P-glycoprotein inhibitor IINon-inhibitor0.8134
Renal organic cation transporterNon-inhibitor0.7971
CYP450 2C9 substrateNon-substrate0.8733
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateSubstrate0.7315
CYP450 1A2 substrateNon-inhibitor0.938
CYP450 2C9 inhibitorNon-inhibitor0.9106
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9247
CYP450 3A4 inhibitorNon-inhibitor0.8308
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9169
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9399
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.1482 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9558
hERG inhibition (predictor II)Inhibitor0.5091
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0ab9-0239000000-6da1b4bf9567b7486622
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-05i4-2930000000-bc11f96b96bcca3051a8
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00dj-3960000000-a7dc9d06200fd3114dc2

Taxonomy

Description
This compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Hydroxysteroids
Direct Parent
21-hydroxysteroids
Alternative Parents
Gluco/mineralocorticoids, progestogins and derivatives / 20-oxosteroids / 11-beta-hydroxysteroids / 17-hydroxysteroids / 3-oxo delta-1,4-steroids / Halogenated steroids / Delta-1,4-steroids / Tertiary alcohols / Alpha-hydroxy ketones / Secondary alcohols
show 8 more
Substituents
Progestogin-skeleton / 21-hydroxysteroid / Pregnane-skeleton / 20-oxosteroid / 3-oxo-delta-1,4-steroid / 3-oxosteroid / 17-hydroxysteroid / 11-hydroxysteroid / 11-beta-hydroxysteroid / 9-halo-steroid
show 23 more
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
11beta-hydroxy steroid, 17alpha-hydroxy steroid, glucocorticoid, 20-oxo steroid, fluorinated steroid, 3-oxo-Delta(1),Delta(4)-steroid, 21-hydroxy steroid (CHEBI:3077)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
Gene Name
NR3C1
Uniprot ID
P04150
Uniprot Name
Glucocorticoid receptor
Molecular Weight
85658.57 Da
References
  1. Tanigawa K, Nagase H, Ohmori K, Tanaka K, Miyake H, Kiniwa M, Ikizawa K: Species-specific differences in the glucocorticoid receptor transactivation function upon binding with betamethasone-esters. Int Immunopharmacol. 2002 Jun;2(7):941-50. [PubMed:12188035]
  2. Aida K, Shi Q, Wang J, VandeBerg JL, McDonald T, Nathanielsz P, Wang XL: The effects of betamethasone (BM) on endothelial nitric oxide synthase (eNOS) expression in adult baboon femoral arterial endothelial cells. J Steroid Biochem Mol Biol. 2004 Aug;91(4-5):219-24. [PubMed:15336699]
  3. Johnstone JF, Bocking AD, Unlugedik E, Challis JR: The effects of chorioamnionitis and betamethasone on 11beta hydroxysteroid dehydrogenase types 1 and 2 and the glucocorticoid receptor in preterm human placenta. J Soc Gynecol Investig. 2005 May;12(4):238-45. [PubMed:15866114]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Academic disertation [Link]
  3. Celestone monograph [File]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inducer
General Function
Oxygen binding
Specific Function
Catalyzes the formation of aromatic C18 estrogens from C19 androgens.
Gene Name
CYP19A1
Uniprot ID
P11511
Uniprot Name
Aromatase
Molecular Weight
57882.48 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Yates CR, Chang C, Kearbey JD, Yasuda K, Schuetz EG, Miller DD, Dalton JT, Swaan PW: Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res. 2003 Nov;20(11):1794-803. [PubMed:14661924]

Drug created on June 13, 2005 07:24 / Updated on November 17, 2018 07:09